NCT05304546View on ClinicalTrials.gov

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

July 17, 2025

Study Completion Date

July 17, 2025

Conditions
Malignant MelanomaMetastatic MelanomaImmunotherapyBRAF V600EMalignant Melanoma Stage IV
Interventions
DRUG

Pembrolizumab

Solution for IV

DRUG

Encorafenib

Oral QD

DRUG

Binimetinib

Oral BID

Trial Locations (1)

522651

Sheba Medical Center, Ramat Gan

All Listed Sponsors
lead

Dr. Ronnie Shapira

OTHER_GOV

NCT05304546 - Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | Biotech Hunter | Biotech Hunter